Abstract
In this work, we examine the way in which stability information obtained from studies on small model peptides correlates with similar information acquired from a protein. The rates of deamidation, oxidation, and diketopiperazine reactions in model peptide systems were compared to those of recombinant human vascular endothelial growth factor (rhVEGF). The N-terminal residues of rhVEGF, a potent mitogen in angiogenesis, are susceptible to the aforementioned reactions. The degradation of the peptides L-Ala-L-Pro-L-Met (APM) and Gly-L-Gsn-L-His-L-His (GQNHH), residues 1–3 and 8–12 of rh VEGF, respectively, and rhVEGF were examined at pH 5 and 8 at 37°C. Capillary electrophoresis and high-performance liquid chromatography (HPLC) stability-indicating assays were developed to monitor the degradation of the penta- and tripeptides, respectively. The degradation of rhVEGF was determined by tryptic mapping and quantified by RP-HPLC. The rates of degradation of both peptides and the protein followed apparent first-order kinetics and increased with increasing pH. The tripeptide APM underwent diketopiperazine formation (Ala-Prodiketopiperazine) and oxidation of the Met residue, whereas the pentapeptide GQNHH degraded via the deamidation pathway. The results indicate that the rates of deamidation and oxidation of the protein are comparable to those observed in the model peptides at both pH values. However, the rate of the diketo-piperazine reaction was slower in the protein than in the model peptide, which may be the result of differences in the cis-trans equilibrium of the X-Pro peptide bonds in the 2 molecules.
Similar content being viewed by others
References
Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851–859.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309.
Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J. 1989;8:3801–3806.
Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci U S A. 1989;86:7311–7315.
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947–11954.
Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi BZ, et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanola cells. J Biol Chem 1995;270:11322–11326.
Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endrocrinol. 1991;5:1806–1814.
Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem. 1991;47:211–218.
P’tgens AJG, Lubsen NH, van Altena MC, Vermeulen R, Bakker A, Shoenmakers J, et al. Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem. 1994;269:32879–32885.
Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, De Vos AM, Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A. 1997;94:7192–7197.
Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem. 1992;267:26031–26037.
Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, et al. The carboxyl-terminal domain (111–165) of vascular endothelial growth is critical for its mitogenic potency. J Biol Chem. 1996;271:7788–7795.
Goolcharran C, Stauffer LL. Cleland JL. Borchardt RT. The effects of a histidine residue on the C-terminal side of an asparaginyl residue on the rate of deamidation using model pentapeptides. J Pharm Sci. (submitted).
Goolcharran C, Borchardt RT. Kinetics of diketopiperazine formation using model peptides. J Pharm Sci. 1998;87:283–288.
Purdie J, Benoiton NL. Piperazinedione formation from esters of dipeptides containing glycine, alanine, and sarcosine: the kinetics in aqueous solution. J Chem Soc. 1973;13:1845–1852.
Levitt M. Effect of proline residue on protein folding. J Mol Biol. 1981;145:251–263.
Ramachandran GN, Mitra AK. An explanation for the rare occurrence of cis peptide units in proteins and polypeptides. J Mol Biol. 1976;107:85–92.
Stein RL. Mechanism of enzymatic and nonenzymatic prolyl cis-trans isomerization. In: Anfinsen CB, Edsall JT, Richards FM, Eisenberg DS, eds. Advances in Protein Chemistry. New York: Academic Press; 1993;1–24.
Patel K, Borchardt RT. Chemical pathways of peptide degradation. II. Kinetics of deamidation of an asparaginyl residue in a model hexapeptide. Pharm Res. 1990;7:703–711.
Christinger HW, Muller YA, Berleau LT, Keyt BA, Cunningham BC, Ferrara N, et al. Crystallization of the receptor binding domain of vascular endothelial growth factor. Proteins. 1996;26:353–357.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published March 17. 2000.
Rights and permissions
About this article
Cite this article
Goolcharran, C., Jones, A.J.S. & Borchardt, R.T. Comparison of the rates of deamidation, diketopiperazine formation, and oxidation in recombinant human vascular endothelial growth factor and model peptides. AAPS PharmSci 2, 5 (2000). https://doi.org/10.1208/ps020105
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/ps020105